[{"id":"0bbfcb8d-b12f-4606-81d4-6f0ddf735e01","acronym":"H3B-6545-G000-102","url":"https://clinicaltrials.gov/study/NCT04288089","created_at":"2021-01-18T20:48:47.833Z","updated_at":"2024-07-02T16:35:12.382Z","phase":"Phase 1","brief_title":"A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer","source_id_and_acronym":"NCT04288089 - H3B-6545-G000-102","lead_sponsor":"Eisai Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • H3B-6545"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 04/01/2020","start_date":" 04/01/2020","primary_txt":" Primary completion: 09/16/2022","primary_completion_date":" 09/16/2022","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2024-03-28"},{"id":"2f8a360e-0756-4c29-9da9-648e54e67f50","acronym":"H3B-6545-A001-101","url":"https://clinicaltrials.gov/study/NCT03250676","created_at":"2021-01-17T17:33:34.840Z","updated_at":"2024-07-02T16:35:25.240Z","phase":"Phase 1/2","brief_title":"Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT03250676 - H3B-6545-A001-101","lead_sponsor":"Eisai Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER Y537S • ER D538G • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER Y537S • ER D538G • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e H3B-6545"],"overall_status":"Completed","enrollment":" Enrollment 206","initiation":"Initiation: 08/17/2017","start_date":" 08/17/2017","primary_txt":" Primary completion: 10/26/2023","primary_completion_date":" 10/26/2023","study_txt":" Completion: 10/26/2023","study_completion_date":" 10/26/2023","last_update_posted":"2023-12-25"},{"id":"a713c467-c701-4e26-8cb2-919a47bdfeb5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04568902","created_at":"2021-01-18T21:49:17.382Z","updated_at":"2024-07-02T16:35:25.307Z","phase":"Phase 1","brief_title":"Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","source_id_and_acronym":"NCT04568902","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e H3B-6545"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 09/30/2020","start_date":" 09/30/2020","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2023-12-22"}]